Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Haleon PLC Sponsored ADR ( (HLN) ) just unveiled an announcement.
On September 1, 2025, Haleon PLC announced the purchase of 2,062,463 ordinary shares for cancellation as part of the second tranche of its share buyback program initiated on July 31, 2025. This transaction, completed on August 29, 2025, is part of Haleon’s strategic efforts to manage its capital structure and enhance shareholder value, potentially impacting its market positioning and investor relations.
The most recent analyst rating on (HLN) stock is a Hold with a $10.50 price target. To see the full list of analyst forecasts on Haleon PLC Sponsored ADR stock, see the HLN Stock Forecast page.
Spark’s Take on HLN Stock
According to Spark, TipRanks’ AI Analyst, HLN is a Neutral.
Haleon PLC’s overall stock score reflects a strong financial position and operational improvements, particularly in international markets. However, challenges in North America and stagnant revenue growth weigh on the score. Technical indicators and valuation suggest moderate potential for growth, with no significant corporate events impacting the assessment.
To see Spark’s full report on HLN stock, click here.
More about Haleon PLC Sponsored ADR
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with a human touch. The company’s product portfolio includes Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health, featuring well-known brands like Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren.
Average Trading Volume: 11,809,654
Technical Sentiment Signal: Buy
Current Market Cap: $44B
For an in-depth examination of HLN stock, go to TipRanks’ Overview page.